ID   PAX2_HUMAN              Reviewed;         417 AA.
AC   Q02962; Q15105; Q15110; Q15837; Q5SZP2; Q5SZP3;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   10-FEB-2009, sequence version 4.
DT   07-APR-2021, entry version 215.
DE   RecName: Full=Paired box protein Pax-2;
GN   Name=PAX2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Kidney;
RX   PubMed=1378753;
RA   Eccles M.R., Wallis L.J., Fidler A.E., Spurr N.K., Goodfellow P.J.,
RA   Reeve A.E.;
RT   "Expression of the PAX2 gene in human fetal kidney and Wilms' tumor.";
RL   Cell Growth Differ. 3:279-289(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RC   TISSUE=Kidney cortex;
RX   PubMed=7819127;
RA   Ward T.A., Nebel A., Reeve A.E., Eccles M.R.;
RT   "Alternative messenger RNA forms and open reading frames within an
RT   additional conserved region of the human PAX-2 gene.";
RL   Cell Growth Differ. 5:1015-1021(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORM 1).
RX   PubMed=8661132; DOI=10.1006/geno.1996.0350;
RA   Sanyanusin P., Norrish J.H., Ward T.A., Nebel A., McNoe L.A., Eccles M.R.;
RT   "Genomic structure of the human PAX2 gene.";
RL   Genomics 35:258-261(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-136.
RX   PubMed=7981748; DOI=10.1038/ng0493-292;
RA   Stapleton P., Weith A., Urbanek P., Kozmik Z., Busslinger M.;
RT   "Chromosomal localization of seven PAX genes and cloning of a novel family
RT   member, PAX-9.";
RL   Nat. Genet. 3:292-298(1993).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-226, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [8]
RP   INTERACTION WITH EGLN3.
RX   PubMed=21575608; DOI=10.1016/j.bbrc.2011.05.012;
RA   Yan B., Jiao S., Zhang H.S., Lv D.D., Xue J., Fan L., Wu G.H., Fang J.;
RT   "Prolyl hydroxylase domain protein 3 targets Pax2 for destruction.";
RL   Biochem. Biophys. Res. Commun. 409:315-320(2011).
RN   [9]
RP   INVOLVEMENT IN RENAL HYPODYSPLASIA, AND VARIANT GLU-24.
RX   PubMed=21380624; DOI=10.1007/s00467-011-1826-9;
RA   Thomas R., Sanna-Cherchi S., Warady B.A., Furth S.L., Kaskel F.J.,
RA   Gharavi A.G.;
RT   "HNF1B and PAX2 mutations are a common cause of renal hypodysplasia in the
RT   CKiD cohort.";
RL   Pediatr. Nephrol. 26:897-903(2011).
RN   [10]
RP   VARIANTS PAPRS GLU-THR-75 INS AND SER-76.
RX   PubMed=9760197; DOI=10.1007/s004390050798;
RA   Devriendt K., Matthijs G., van Damme B., van Caesbroeck D., Eccles M.R.,
RA   Vanrenterghem Y., Fryns J.-P., Leys A.;
RT   "Missense mutation and hexanucleotide duplication in the PAX2 gene in two
RT   unrelated families with renal-coloboma syndrome (MIM 120330).";
RL   Hum. Genet. 103:149-153(1998).
RN   [11]
RP   VARIANT VAL-334.
RX   PubMed=11180607;
RX   DOI=10.1002/1098-1004(200102)17:2<155::aid-humu16>3.0.co;2-9;
RA   Gelb A.C., Manligas G.S., Gharaybeh S., Schimmenti L.A.;
RT   "Identification of two novel polymorphisms (g.903C>T and g.1544C>T) in the
RT   PAX2 gene.";
RL   Hum. Mutat. 17:155-155(2001).
RN   [12]
RP   VARIANT PAPRS 39-GLN-ARG-40 DEL.
RX   PubMed=11168927; DOI=10.1046/j.1523-1755.2001.059002457.x;
RA   Salomon R., Tellier A.-L., Attie-Bitach T., Amiel J., Vekemans M.,
RA   Lyonnet S., Dureau P., Niaudet P., Gubler M.-C., Broyer M.;
RT   "PAX2 mutations in oligomeganephronia.";
RL   Kidney Int. 59:457-462(2001).
RN   [13]
RP   VARIANT PAPRS THR-71.
RX   PubMed=15652857; DOI=10.1016/j.ajo.2004.07.021;
RA   Higashide T., Wada T., Sakurai M., Yokoyama H., Sugiyama K.;
RT   "Macular abnormalities and optic disk anomaly associated with a new PAX2
RT   missense mutation.";
RL   Am. J. Ophthalmol. 139:203-205(2005).
RN   [14]
RP   VARIANT PAPRS HIS-130.
RX   PubMed=19954729; DOI=10.5414/cnp72497;
RA   Miyazawa T., Nakano M., Takemura Y., Miyazaki K., Yanagida H., Fujita S.,
RA   Sugimoto K., Okada M., Takemura T.;
RT   "A case of renal-coloboma syndrome associated with mental developmental
RT   delay exhibiting a novel PAX2 gene mutation.";
RL   Clin. Nephrol. 72:497-500(2009).
RN   [15]
RP   VARIANTS PAPRS VAL-25; ARG-33; ILE-61; ASN-61; 62-HIS--SER-66 DEL; PRO-69;
RP   THR-75 INS; SER-84; SER-ILE-LYS-PRO-GLY-VAL-ILE-GLY-84 INS; PRO-117 AND
RP   SER-130, AND VARIANTS THR-160; ASN-164; THR-175; VAL-334 AND ASN-387.
RX   PubMed=22213154; DOI=10.1002/humu.22020;
RA   Bower M., Salomon R., Allanson J., Antignac C., Benedicenti F., Benetti E.,
RA   Binenbaum G., Jensen U.B., Cochat P., DeCramer S., Dixon J., Drouin R.,
RA   Falk M.J., Feret H., Gise R., Hunter A., Johnson K., Kumar R.,
RA   Lavocat M.P., Martin L., Moriniere V., Mowat D., Murer L., Nguyen H.T.,
RA   Peretz-Amit G., Pierce E., Place E., Rodig N., Salerno A., Sastry S.,
RA   Sato T., Sayer J.A., Schaafsma G.C., Shoemaker L., Stockton D.W., Tan W.H.,
RA   Tenconi R., Vanhille P., Vats A., Wang X., Warman B., Weleber R.G.,
RA   White S.M., Wilson-Brackett C., Zand D.J., Eccles M., Schimmenti L.A.,
RA   Heidet L.;
RT   "Update of PAX2 mutations in renal coloboma syndrome and establishment of a
RT   locus-specific database.";
RL   Hum. Mutat. 33:457-466(2012).
RN   [16]
RP   INVOLVEMENT IN FSGS7, VARIANTS FSGS7 GLN-56; LEU-80; PHE-133; ALA-150;
RP   ASN-164 AND ARG-189, CHARACTERIZATION OF VARIANTS FSGS7 GLN-56; LEU-80;
RP   PHE-133 AND ARG-189, VARIANTS PAPRS GLY-2; VAL-139; VAL-295; PRO-296;
RP   SER-298 AND ALA-329, INTERACTION WITH TLE4, AND FUNCTION.
RX   PubMed=24676634; DOI=10.1681/asn.2013070686;
RA   Barua M., Stellacci E., Stella L., Weins A., Genovese G., Muto V.,
RA   Caputo V., Toka H.R., Charoonratana V.T., Tartaglia M., Pollak M.R.;
RT   "Mutations in PAX2 associate with adult-onset FSGS.";
RL   J. Am. Soc. Nephrol. 25:1942-1953(2014).
CC   -!- FUNCTION: Transcription factor that may have a role in kidney cell
CC       differentiation (PubMed:24676634). Has a critical role in the
CC       development of the urogenital tract, the eyes, and the CNS.
CC       {ECO:0000269|PubMed:24676634}.
CC   -!- SUBUNIT: Interacts with ELGN3; the interaction targets PAX2 for
CC       destruction. Interacts with TLE4. {ECO:0000269|PubMed:21575608,
CC       ECO:0000269|PubMed:24676634}.
CC   -!- INTERACTION:
CC       Q02962; O60663-2: LMX1B; NbExp=3; IntAct=EBI-1805765, EBI-10258690;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q02962-1; Sequence=Displayed;
CC       Name=2; Synonyms=Fetal kidney;
CC         IsoId=Q02962-2; Sequence=VSP_002346;
CC       Name=3;
CC         IsoId=Q02962-3; Sequence=VSP_002345;
CC       Name=4;
CC         IsoId=Q02962-4; Sequence=VSP_002345, VSP_002346;
CC   -!- TISSUE SPECIFICITY: Expressed in primitive cells of the kidney, ureter,
CC       eye, ear and central nervous system.
CC   -!- DEVELOPMENTAL STAGE: Mainly in fetal kidney and juvenile nephrogenic
CC       rests.
CC   -!- DISEASE: Papillorenal syndrome (PAPRS) [MIM:120330]: An autosomal
CC       dominant disorder characterized by both ocular and renal anomalies, but
CC       may also include vesicoureteral reflux, high frequency hearing loss,
CC       central nervous system anomalies, and/or genital anomalies. Eye
CC       anomalies in this disorder consist of a wide and sometimes excavated
CC       dysplastic optic disk with the emergence of the retinal vessels from
CC       the periphery of the disk, designated optic nerve coloboma or 'morning
CC       glory' anomaly. Associated findings may include a small corneal
CC       diameter, retinal coloboma, scleral staphyloma, optic nerve cyst,
CC       microphthalmia, and pigmentary macular dysplasia. The kidneys are small
CC       and abnormally formed (renal hypodysplasia), and have fewer than the
CC       normal number of glomeruli, which are enlarged (oligomeganephronia).
CC       These ocular and renal anomalies result in decreased visual acuity and
CC       retinal detachment, as well as hypertension, proteinuria, and renal
CC       insufficiency that frequently progresses to end-stage renal disease.
CC       {ECO:0000269|PubMed:11168927, ECO:0000269|PubMed:15652857,
CC       ECO:0000269|PubMed:19954729, ECO:0000269|PubMed:22213154,
CC       ECO:0000269|PubMed:24676634, ECO:0000269|PubMed:9760197}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Focal segmental glomerulosclerosis 7 (FSGS7) [MIM:616002]: A
CC       renal pathology defined by the presence of segmental sclerosis in
CC       glomeruli and resulting in proteinuria, reduced glomerular filtration
CC       rate and progressive decline in renal function. Renal insufficiency
CC       often progresses to end-stage renal disease, a highly morbid state
CC       requiring either dialysis therapy or kidney transplantation.
CC       {ECO:0000269|PubMed:24676634}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- WEB RESOURCE: Name=PAX2 mutation db;
CC       URL="http://www.hgu.mrc.ac.uk/Softdata/PAX2/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PAX2ID41642ch10q24.html";
CC   -!- WEB RESOURCE: Name=PAX2 variant database paired box 2 (PAX2);
CC       Note=Leiden Open Variation Database (LOVD);
CC       URL="https://databases.lovd.nl/shared/genes/PAX2";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M89470; AAA60024.1; -; mRNA.
DR   EMBL; L25597; AAA36417.1; -; mRNA.
DR   EMBL; U45255; AAC63385.1; -; Genomic_DNA.
DR   EMBL; U45245; AAC63385.1; JOINED; Genomic_DNA.
DR   EMBL; U45246; AAC63385.1; JOINED; Genomic_DNA.
DR   EMBL; U45247; AAC63385.1; JOINED; Genomic_DNA.
DR   EMBL; U45248; AAC63385.1; JOINED; Genomic_DNA.
DR   EMBL; U45249; AAC63385.1; JOINED; Genomic_DNA.
DR   EMBL; U45250; AAC63385.1; JOINED; Genomic_DNA.
DR   EMBL; U45251; AAC63385.1; JOINED; Genomic_DNA.
DR   EMBL; U45253; AAC63385.1; JOINED; Genomic_DNA.
DR   EMBL; U45254; AAC63385.1; JOINED; Genomic_DNA.
DR   EMBL; AL138762; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL589862; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471066; EAW49812.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49813.1; -; Genomic_DNA.
DR   EMBL; L09747; AAC41711.1; -; Genomic_DNA.
DR   EMBL; L09748; AAC41711.1; JOINED; Genomic_DNA.
DR   EMBL; L09746; AAC41711.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS41561.1; -. [Q02962-3]
DR   CCDS; CCDS7499.1; -. [Q02962-4]
DR   PIR; A49008; A49008.
DR   RefSeq; NP_000269.3; NM_000278.4. [Q02962-3]
DR   RefSeq; NP_001291498.1; NM_001304569.1.
DR   RefSeq; NP_003978.3; NM_003987.4. [Q02962-1]
DR   RefSeq; NP_003979.2; NM_003988.4. [Q02962-4]
DR   RefSeq; NP_003980.3; NM_003989.4.
DR   RefSeq; NP_003981.3; NM_003990.4.
DR   SMR; Q02962; -.
DR   BioGRID; 111110; 22.
DR   IntAct; Q02962; 18.
DR   MINT; Q02962; -.
DR   STRING; 9606.ENSP00000359319; -.
DR   iPTMnet; Q02962; -.
DR   PhosphoSitePlus; Q02962; -.
DR   BioMuta; PAX2; -.
DR   DMDM; 223590261; -.
DR   MassIVE; Q02962; -.
DR   MaxQB; Q02962; -.
DR   PaxDb; Q02962; -.
DR   PeptideAtlas; Q02962; -.
DR   PRIDE; Q02962; -.
DR   ProteomicsDB; 58144; -. [Q02962-1]
DR   ProteomicsDB; 58145; -. [Q02962-2]
DR   ProteomicsDB; 58146; -. [Q02962-3]
DR   ProteomicsDB; 58147; -. [Q02962-4]
DR   Antibodypedia; 31200; 449 antibodies.
DR   DNASU; 5076; -.
DR   Ensembl; ENST00000355243; ENSP00000347385; ENSG00000075891. [Q02962-3]
DR   Ensembl; ENST00000370296; ENSP00000359319; ENSG00000075891. [Q02962-4]
DR   Ensembl; ENST00000428433; ENSP00000396259; ENSG00000075891. [Q02962-1]
DR   GeneID; 5076; -.
DR   KEGG; hsa:5076; -.
DR   UCSC; uc001krl.4; human. [Q02962-1]
DR   CTD; 5076; -.
DR   DisGeNET; 5076; -.
DR   GeneCards; PAX2; -.
DR   GeneReviews; PAX2; -.
DR   HGNC; HGNC:8616; PAX2.
DR   HPA; ENSG00000075891; Tissue enhanced (ductus deferens, epididymis, kidney).
DR   MalaCards; PAX2; -.
DR   MIM; 120330; phenotype.
DR   MIM; 167409; gene.
DR   MIM; 616002; phenotype.
DR   neXtProt; NX_Q02962; -.
DR   OpenTargets; ENSG00000075891; -.
DR   Orphanet; 656; Genetic steroid-resistant nephrotic syndrome.
DR   Orphanet; 1475; Renal coloboma syndrome.
DR   Orphanet; 97362; Renal hypoplasia, bilateral.
DR   PharmGKB; PA32956; -.
DR   VEuPathDB; HostDB:ENSG00000075891.21; -.
DR   eggNOG; KOG3862; Eukaryota.
DR   GeneTree; ENSGT00940000157412; -.
DR   InParanoid; Q02962; -.
DR   OMA; DPVHIRG; -.
DR   OrthoDB; 592933at2759; -.
DR   PhylomeDB; Q02962; -.
DR   TreeFam; TF315397; -.
DR   PathwayCommons; Q02962; -.
DR   SignaLink; Q02962; -.
DR   SIGNOR; Q02962; -.
DR   BioGRID-ORCS; 5076; 7 hits in 1009 CRISPR screens.
DR   ChiTaRS; PAX2; human.
DR   GeneWiki; PAX2; -.
DR   GenomeRNAi; 5076; -.
DR   Pharos; Q02962; Tbio.
DR   PRO; PR:Q02962; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; Q02962; protein.
DR   Bgee; ENSG00000075891; Expressed in cortex of kidney and 83 other tissues.
DR   ExpressionAtlas; Q02962; baseline and differential.
DR   Genevisible; Q02962; HS.
DR   GO; GO:0034451; C:centriolar satellite; IDA:BHF-UCL.
DR   GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR   GO; GO:0005764; C:lysosome; IEA:Ensembl.
DR   GO; GO:0005815; C:microtubule organizing center; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; ISS:UniProtKB.
DR   GO; GO:0032993; C:protein-DNA complex; ISS:UniProtKB.
DR   GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0000976; F:transcription regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0048856; P:anatomical structure development; IBA:GO_Central.
DR   GO; GO:0007409; P:axonogenesis; TAS:ProtInc.
DR   GO; GO:0048854; P:brain morphogenesis; ISS:UniProtKB.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; IEP:UniProtKB.
DR   GO; GO:0043010; P:camera-type eye development; ISS:UniProtKB.
DR   GO; GO:0001709; P:cell fate determination; ISS:UniProtKB.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; ISS:UniProtKB.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; ISS:UniProtKB.
DR   GO; GO:0071300; P:cellular response to retinoic acid; ISS:UniProtKB.
DR   GO; GO:0090102; P:cochlea development; ISS:UniProtKB.
DR   GO; GO:0090103; P:cochlea morphogenesis; ISS:UniProtKB.
DR   GO; GO:0010001; P:glial cell differentiation; ISS:UniProtKB.
DR   GO; GO:0042472; P:inner ear morphogenesis; ISS:UniProtKB.
DR   GO; GO:0060231; P:mesenchymal to epithelial transition; ISS:UniProtKB.
DR   GO; GO:0003337; P:mesenchymal to epithelial transition involved in metanephros morphogenesis; ISS:UniProtKB.
DR   GO; GO:0007501; P:mesodermal cell fate specification; ISS:UniProtKB.
DR   GO; GO:0001823; P:mesonephros development; ISS:UniProtKB.
DR   GO; GO:0072205; P:metanephric collecting duct development; ISS:UniProtKB.
DR   GO; GO:0072221; P:metanephric distal convoluted tubule development; ISS:UniProtKB.
DR   GO; GO:0072207; P:metanephric epithelium development; IEP:UniProtKB.
DR   GO; GO:0072162; P:metanephric mesenchymal cell differentiation; ISS:UniProtKB.
DR   GO; GO:0072075; P:metanephric mesenchyme development; ISS:UniProtKB.
DR   GO; GO:0072289; P:metanephric nephron tubule formation; ISS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:1900215; P:negative regulation of apoptotic process involved in metanephric collecting duct development; ISS:UniProtKB.
DR   GO; GO:1900218; P:negative regulation of apoptotic process involved in metanephric nephron tubule development; ISS:UniProtKB.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:UniProtKB.
DR   GO; GO:0072305; P:negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis; ISS:UniProtKB.
DR   GO; GO:1900212; P:negative regulation of mesenchymal cell apoptotic process involved in metanephros development; ISS:UniProtKB.
DR   GO; GO:0043069; P:negative regulation of programmed cell death; ISS:UniProtKB.
DR   GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IMP:UniProtKB.
DR   GO; GO:0072179; P:nephric duct formation; ISS:UniProtKB.
DR   GO; GO:0001843; P:neural tube closure; ISS:UniProtKB.
DR   GO; GO:0061360; P:optic chiasma development; ISS:UniProtKB.
DR   GO; GO:0002072; P:optic cup morphogenesis involved in camera-type eye development; ISS:UniProtKB.
DR   GO; GO:0021554; P:optic nerve development; ISS:UniProtKB.
DR   GO; GO:0021631; P:optic nerve morphogenesis; ISS:UniProtKB.
DR   GO; GO:0021633; P:optic nerve structural organization; ISS:UniProtKB.
DR   GO; GO:0090190; P:positive regulation of branching involved in ureteric bud morphogenesis; ISS:UniProtKB.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IDA:UniProtKB.
DR   GO; GO:0072108; P:positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis; ISS:UniProtKB.
DR   GO; GO:2000594; P:positive regulation of metanephric DCT cell differentiation; ISS:UniProtKB.
DR   GO; GO:0072300; P:positive regulation of metanephric glomerulus development; ISS:UniProtKB.
DR   GO; GO:2000597; P:positive regulation of optic nerve formation; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0039003; P:pronephric field specification; ISS:UniProtKB.
DR   GO; GO:0048793; P:pronephros development; ISS:UniProtKB.
DR   GO; GO:0043491; P:protein kinase B signaling; ISS:UniProtKB.
DR   GO; GO:0072593; P:reactive oxygen species metabolic process; ISS:UniProtKB.
DR   GO; GO:0072307; P:regulation of metanephric nephron tubule epithelial cell differentiation; ISS:UniProtKB.
DR   GO; GO:0035566; P:regulation of metanephros size; IMP:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0031667; P:response to nutrient levels; IEA:Ensembl.
DR   GO; GO:0003406; P:retinal pigment epithelium development; ISS:UniProtKB.
DR   GO; GO:0048863; P:stem cell differentiation; ISS:UniProtKB.
DR   GO; GO:0072189; P:ureter development; ISS:UniProtKB.
DR   GO; GO:0035799; P:ureter maturation; ISS:UniProtKB.
DR   GO; GO:0001655; P:urogenital system development; ISS:UniProtKB.
DR   GO; GO:0021650; P:vestibulocochlear nerve formation; ISS:UniProtKB.
DR   GO; GO:0007601; P:visual perception; TAS:ProtInc.
DR   CDD; cd00131; PAX; 1.
DR   Gene3D; 1.10.10.10; -; 2.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR043182; PAIRED_DNA-bd_dom.
DR   InterPro; IPR001523; Paired_dom.
DR   InterPro; IPR022130; Pax2_C.
DR   InterPro; IPR043565; PAX_fam.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   PANTHER; PTHR45636; PTHR45636; 1.
DR   Pfam; PF00292; PAX; 1.
DR   Pfam; PF12403; Pax2_C; 1.
DR   PRINTS; PR00027; PAIREDBOX.
DR   SMART; SM00351; PAX; 1.
DR   SUPFAM; SSF46689; SSF46689; 1.
DR   PROSITE; PS00034; PAIRED_1; 1.
DR   PROSITE; PS51057; PAIRED_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Developmental protein; Differentiation;
KW   Disease variant; DNA-binding; Nucleus; Paired box; Phosphoprotein;
KW   Reference proteome; Transcription; Transcription regulation.
FT   CHAIN           1..417
FT                   /note="Paired box protein Pax-2"
FT                   /id="PRO_0000050175"
FT   DNA_BIND        16..142
FT                   /note="Paired"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00381"
FT   REGION          19..75
FT                   /note="PAI subdomain"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00381"
FT   REGION          94..142
FT                   /note="RED subdomain"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00381"
FT   MOD_RES         226
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   VAR_SEQ         206..228
FT                   /note="Missing (in isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:1378753,
FT                   ECO:0000303|PubMed:7819127"
FT                   /id="VSP_002345"
FT   VAR_SEQ         364..417
FT                   /note="GSEFSGNPYSHPQYTAYNEAWRFSNPALLSSPYYYSAAPRGSAPAAAAAAYD
FT                   RH -> EAAVGPSSSLMSKPGRKLAEVPPCVQPTGASSPATRTATPSTRPTTRLGDSAT
FT                   PPY (in isoform 2 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:7819127"
FT                   /id="VSP_002346"
FT   VARIANT         2
FT                   /note="D -> G (in PAPRS)"
FT                   /evidence="ECO:0000269|PubMed:24676634"
FT                   /id="VAR_071937"
FT   VARIANT         24
FT                   /note="G -> E (probable disease-associated variant found in
FT                   a patient with non-syndromic renal hypodysplasia;
FT                   dbSNP:rs201239919)"
FT                   /evidence="ECO:0000269|PubMed:21380624"
FT                   /id="VAR_068079"
FT   VARIANT         25
FT                   /note="G -> V (in PAPRS)"
FT                   /evidence="ECO:0000269|PubMed:22213154"
FT                   /id="VAR_068080"
FT   VARIANT         33
FT                   /note="L -> R (in PAPRS)"
FT                   /evidence="ECO:0000269|PubMed:22213154"
FT                   /id="VAR_068081"
FT   VARIANT         39..40
FT                   /note="Missing (in PAPRS; the patient manifests
FT                   oligomeganephronia and bilateral optic nerve coloboma)"
FT                   /evidence="ECO:0000269|PubMed:11168927"
FT                   /id="VAR_012442"
FT   VARIANT         56
FT                   /note="R -> Q (in FSGS7; decreased DNA-binding capability
FT                   and transactivation ability; dbSNP:rs587777708)"
FT                   /evidence="ECO:0000269|PubMed:24676634"
FT                   /id="VAR_071938"
FT   VARIANT         61
FT                   /note="S -> I (in PAPRS)"
FT                   /evidence="ECO:0000269|PubMed:22213154"
FT                   /id="VAR_068082"
FT   VARIANT         61
FT                   /note="S -> N (in PAPRS)"
FT                   /evidence="ECO:0000269|PubMed:22213154"
FT                   /id="VAR_068083"
FT   VARIANT         62..66
FT                   /note="Missing (in PAPRS)"
FT                   /evidence="ECO:0000269|PubMed:22213154"
FT                   /id="VAR_068084"
FT   VARIANT         69
FT                   /note="L -> P (in PAPRS)"
FT                   /evidence="ECO:0000269|PubMed:22213154"
FT                   /id="VAR_068085"
FT   VARIANT         71
FT                   /note="R -> T (in PAPRS; dbSNP:rs104894170)"
FT                   /evidence="ECO:0000269|PubMed:15652857"
FT                   /id="VAR_068086"
FT   VARIANT         75
FT                   /note="T -> TET (in PAPRS)"
FT                   /id="VAR_003788"
FT   VARIANT         75
FT                   /note="T -> TT (in PAPRS)"
FT                   /evidence="ECO:0000269|PubMed:22213154"
FT                   /id="VAR_068087"
FT   VARIANT         76
FT                   /note="G -> S (in PAPRS; dbSNP:rs79555199)"
FT                   /evidence="ECO:0000269|PubMed:9760197"
FT                   /id="VAR_003789"
FT   VARIANT         80
FT                   /note="P -> L (in FSGS7; decreased DNA-binding capability
FT                   and transactivation ability; dbSNP:rs1554856032)"
FT                   /evidence="ECO:0000269|PubMed:24676634"
FT                   /id="VAR_071939"
FT   VARIANT         84
FT                   /note="G -> GSIKPGVIG (in PAPRS)"
FT                   /evidence="ECO:0000269|PubMed:22213154"
FT                   /id="VAR_068088"
FT   VARIANT         84
FT                   /note="G -> S (in PAPRS)"
FT                   /evidence="ECO:0000269|PubMed:22213154"
FT                   /id="VAR_068089"
FT   VARIANT         117
FT                   /note="R -> P (in PAPRS)"
FT                   /evidence="ECO:0000269|PubMed:22213154"
FT                   /id="VAR_068090"
FT   VARIANT         130
FT                   /note="P -> H (in PAPRS)"
FT                   /evidence="ECO:0000269|PubMed:19954729"
FT                   /id="VAR_068091"
FT   VARIANT         130
FT                   /note="P -> S (in PAPRS)"
FT                   /evidence="ECO:0000269|PubMed:22213154"
FT                   /id="VAR_068092"
FT   VARIANT         133
FT                   /note="S -> F (in FSGS7; decreased DNA-binding capability
FT                   and transactivation ability)"
FT                   /evidence="ECO:0000269|PubMed:24676634"
FT                   /id="VAR_071940"
FT   VARIANT         139
FT                   /note="I -> V (in PAPRS)"
FT                   /evidence="ECO:0000269|PubMed:24676634"
FT                   /id="VAR_071941"
FT   VARIANT         150
FT                   /note="T -> A (in FSGS7; dbSNP:rs1201078720)"
FT                   /evidence="ECO:0000269|PubMed:24676634"
FT                   /id="VAR_071942"
FT   VARIANT         160
FT                   /note="A -> T (in dbSNP:rs201383632)"
FT                   /evidence="ECO:0000269|PubMed:22213154"
FT                   /id="VAR_068093"
FT   VARIANT         164
FT                   /note="T -> N (in FSGS7; dbSNP:rs370214925)"
FT                   /evidence="ECO:0000269|PubMed:22213154,
FT                   ECO:0000269|PubMed:24676634"
FT                   /id="VAR_068094"
FT   VARIANT         175
FT                   /note="S -> T"
FT                   /evidence="ECO:0000269|PubMed:22213154"
FT                   /id="VAR_068095"
FT   VARIANT         189
FT                   /note="G -> R (in FSGS7; transactivation activity is
FT                   dramatically decreased in presence of TLE4; dramatically
FT                   enhances interaction with TLE4; dbSNP:rs1131692055)"
FT                   /evidence="ECO:0000269|PubMed:24676634"
FT                   /id="VAR_071943"
FT   VARIANT         295
FT                   /note="A -> V (in PAPRS; dbSNP:rs1403345811)"
FT                   /evidence="ECO:0000269|PubMed:24676634"
FT                   /id="VAR_071944"
FT   VARIANT         296
FT                   /note="L -> P (in PAPRS)"
FT                   /evidence="ECO:0000269|PubMed:24676634"
FT                   /id="VAR_071945"
FT   VARIANT         298
FT                   /note="P -> S (in PAPRS; dbSNP:rs893370744)"
FT                   /evidence="ECO:0000269|PubMed:24676634"
FT                   /id="VAR_071946"
FT   VARIANT         329
FT                   /note="T -> A (in PAPRS)"
FT                   /evidence="ECO:0000269|PubMed:24676634"
FT                   /id="VAR_071947"
FT   VARIANT         334
FT                   /note="A -> V (in dbSNP:rs78738655)"
FT                   /evidence="ECO:0000269|PubMed:11180607,
FT                   ECO:0000269|PubMed:22213154"
FT                   /id="VAR_012443"
FT   VARIANT         387
FT                   /note="S -> N (found in a patient with bilateral optic
FT                   nerve colobomas; uncertain pathological significance;
FT                   dbSNP:rs138490772)"
FT                   /evidence="ECO:0000269|PubMed:22213154"
FT                   /id="VAR_068096"
FT   CONFLICT        15..16
FT                   /note="PG -> R (in Ref. 6; AAC41711)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        404
FT                   /note="Missing (in Ref. 1; AAA60024 and 3; AAC63385)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        410
FT                   /note="A -> R (in Ref. 1; AAA60024 and 3; AAC63385)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   417 AA;  44706 MW;  7EA24F9EB8C843F8 CRC64;
     MDMHCKADPF SAMHPGHGGV NQLGGVFVNG RPLPDVVRQR IVELAHQGVR PCDISRQLRV
     SHGCVSKILG RYYETGSIKP GVIGGSKPKV ATPKVVDKIA EYKRQNPTMF AWEIRDRLLA
     EGICDNDTVP SVSSINRIIR TKVQQPFHPT PDGAGTGVTA PGHTIVPSTA SPPVSSASND
     PVGSYSINGI LGIPRSNGEK RKRDEVEVYT DPAHIRGGGG LHLVWTLRDV SEGSVPNGDS
     QSGVDSLRKH LRADTFTQQQ LEALDRVFER PSYPDVFQAS EHIKSEQGNE YSLPALTPGL
     DEVKSSLSAS TNPELGSNVS GTQTYPVVTG RDMASTTLPG YPPHVPPTGQ GSYPTSTLAG
     MVPGSEFSGN PYSHPQYTAY NEAWRFSNPA LLSSPYYYSA APRGSAPAAA AAAYDRH
//
